Analysts See $0.20 EPS for Nautilus, Inc. (NLS); Tapimmune (TPIV) Shorts Up By 140.55%

April 19, 2018 - By Nellie Frank

Nautilus, Inc. (NYSE:NLS) Logo

Tapimmune Inc (NASDAQ:TPIV) had an increase of 140.55% in short interest. TPIV’s SI was 61,100 shares in April as released by FINRA. Its up 140.55% from 25,400 shares previously. With 28,600 avg volume, 2 days are for Tapimmune Inc (NASDAQ:TPIV)’s short sellers to cover TPIV’s short positions. The SI to Tapimmune Inc’s float is 0.61%. The stock decreased 0.64% or $0.02 during the last trading session, reaching $3.09. About 20,899 shares traded. TapImmune, Inc. (NASDAQ:TPIV) has declined 26.26% since April 19, 2017 and is downtrending. It has underperformed by 37.81% the S&P500.

Analysts expect Nautilus, Inc. (NYSE:NLS) to report $0.20 EPS on May, 7.They anticipate $0.06 EPS change or 23.08% from last quarter’s $0.26 EPS. NLS’s profit would be $6.07M giving it 16.88 P/E if the $0.20 EPS is correct. After having $0.27 EPS previously, Nautilus, Inc.’s analysts see -25.93% EPS growth. The stock decreased 1.10% or $0.15 during the last trading session, reaching $13.5. About 61,710 shares traded. Nautilus, Inc. (NYSE:NLS) has declined 26.70% since April 19, 2017 and is downtrending. It has underperformed by 38.25% the S&P500.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease. The company has market cap of $32.84 million. It specializes in the development of immunotherapies targeting womenÂ’s cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers. It currently has negative earnings. The companyÂ’s peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patientÂ’s killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

Since December 14, 2017, it had 0 buys, and 4 insider sales for $449,923 activity. Another trade for 10,700 shares valued at $137,588 was sold by Cazenave Bruce M.. 2,335 shares valued at $30,355 were sold by Collins Jeffery Lynn on Tuesday, March 6.

Among 9 analysts covering Nautilus Group (NYSE:NLS), 5 have Buy rating, 0 Sell and 4 Hold. Therefore 56% are positive. Nautilus Group had 29 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Outperform” rating given on Wednesday, July 6 by Imperial Capital. Imperial Capital downgraded Nautilus, Inc. (NYSE:NLS) on Monday, September 19 to “In-Line” rating. The firm has “Neutral” rating given on Tuesday, March 6 by B. Riley & Co. The firm earned “Buy” rating on Wednesday, September 28 by Wunderlich. The stock has “Outperform” rating by Imperial Capital on Monday, March 13. The company was maintained on Wednesday, May 3 by Imperial Capital. The company was downgraded on Tuesday, October 31 by Lake Street. The stock has “Neutral” rating by DA Davidson on Monday, January 9. The stock of Nautilus, Inc. (NYSE:NLS) has “Hold” rating given on Wednesday, March 7 by Imperial Capital. SunTrust maintained the stock with “Hold” rating in Monday, March 5 report.

Nautilus, Inc. (NYSE:NLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>